

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康臣藥業集團有限公司**  
**CONSUN PHARMACEUTICAL GROUP LIMITED**

*(Incorporated in Cayman Islands with limited liability)*

**(Stock Code: 1681)**

**VOLUNTARY ANNOUNCEMENT  
IN RELATION TO THE STRATEGIC COOPERATION AGREEMENT AND  
THE PROJECT AGREEMENTS ENTERED INTO WITH  
WUXI APPTEC (SHANGHAI) CO., LTD.**

The board of directors (the “**Board**”) of Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Guangzhou Consun Pharmaceutical Company Limited\* (廣州康臣藥業有限公司) (“**GZ Consun**”), a wholly-owned subsidiary of the Company, and WuXi AppTec (Shanghai) Co., Ltd.\* (上海藥明康德新藥開發有限公司) (“**WXAT Shanghai**”) (i) entered into a strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) on 27 June 2021 in relation to the strategic cooperation in the research and development of certain innovative drugs (the “**Strategic Cooperation**”); (ii) entered into an agreement regarding the research and development project of a Class I new drug used for acute kidney injury (“**Project Agreement-I**”) on 28 June 2021; and (iii) entered into an agreement regarding the research and development project of a Class I new drug used for uremic pruritus (“**Project Agreement-II**”, together with Project Agreement-I, the “**Project Agreements**”) on 28 June 2021.

**STRATEGIC COOPERATION AGREEMENT**

Pursuant to the Strategic Cooperation Agreement, GZ Consun and WXAT Shanghai intend to cooperate in the research and development of innovative small molecule drugs, which focus on curing kidney diseases and its complications, and may subsequently extend to other innovative drugs in other disease fields. GZ Consun and WXAT Shanghai will regularly discuss the cooperation opportunities for the research and development of new drugs in the field of kidney diseases. Both parties took each other as an important strategic cooperation partner based on the principle of joint investment, joint development and shared risks.

The Strategic Cooperation Agreement provides a strategic cooperation framework between GZ Consun and WXAT Shanghai. The terms of cooperation contemplated under the Strategic Cooperation Agreement are subject to the terms of any specific agreements which GZ Consun and WXAT Shanghai may subsequently enter into from time to time. If any transaction contemplated under the specific agreement constitutes a notifiable transaction for the Company under the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), further announcement(s) will be made by the Company as and when appropriate in compliance with the Listing Rules.

## PROJECT AGREEMENTS

Project Agreement-I is targeted for a research and development project of a Class I new drug used for acute kidney injury, with acute kidney injury as the preferred indication. WXAT Shanghai shall undertake the pre-clinical research and development work, and GZ Consun shall submit application for phase I clinical trial to the National Medical Products Administration (the “NMPA”) of China and obtain clinical implied approval, as well as assume subsequent clinical development and commercialization efforts.

The intellectual property rights of the preclinical candidate compounds (PCC) under Project Agreement-I are jointly held by both GZ Consun and WXAT Shanghai. The corresponding relevant clinical trial application rights and approval of production under this project are proprietarily owned by GZ Consun.

Project Agreement-II is targeted for a research and development project of a Class I new drug used for uremic pruritus, with uremic pruritus as the preferred indication. WXAT Shanghai shall undertake the pre-clinical research and development work, and GZ Consun shall submit application for phase I clinical trial to the NMPA and obtain clinical implied approval, as well as assume subsequent clinical development and commercialization efforts.

The intellectual property rights of the preclinical candidate compounds (PCC) under Project Agreement-II are jointly held by both GZ Consun and WXAT Shanghai. The corresponding relevant clinical trial application rights and approval of production under this project are proprietarily owned by GZ Consun.

## INFORMATION OF WXAT SHANGHAI

WXAT Shanghai is a company established in the People’s Republic of China (the “PRC”) with limited liability and a direct wholly-owned subsidiary of WuXi AppTec Co., Ltd.\* (無錫藥明康德新藥開發股份有限公司) (“WuXi AppTec”), a joint stock company incorporated in the PRC, the H Shares of which are listed on the Main Board of the Stock Exchange (stock code: 02359.HK) and the A Shares of which are listed on the Shanghai Stock Exchange (stock code: 603259.SH).

WXAT Shanghai is principally engaged in the discovery, research and development of small molecule drugs.

To the best of the Board’s knowledge, information and belief, and having made all reasonable enquiries, WXAT Shanghai and its ultimate beneficial owners are all third parties independent of the Company and its connected persons (as defined in the Listing Rules).

## **REASONS AND BENEFITS FOR THE STRATEGIC COOPERATION AGREEMENT AND THE PROJECT AGREEMENTS**

The Group is an integrated pharmaceutical group principally engaged in the research, manufacturing and marketing of modern Chinese medicines and medical contrast medium in the PRC.

The Group will further improve its research and development capabilities and level of innovation through the cooperation with WXAT Shanghai. The Strategic Cooperation and the cooperation contemplated under the Project Agreements will give full play to the strengths of both parties through complementary advantages and strong alliances to achieve a win-win in the areas of new drugs research and development and product marketing, and thus lay the foundation for the Company to grow into an “all-round nephrology flagship”.

The Board is of the view that, the Strategic Cooperation and the cooperation contemplated under the Project Agreements will enable the Company to develop a broader and newer research and development pipeline in the field of kidney disease drugs, further enhancing its overall strength and competitive edge in the market, which are in line with the company’s development strategy and are in the interests of the Company and its shareholders as a whole.

By order of the Board  
**Consun Pharmaceutical Group Limited**  
**AN Meng**  
*Chairman*

Hong Kong, 18 July 2021

*As of the date of this announcement, the Board comprises Mr. AN Meng, Ms. LI Qian, Professor ZHU Quan and Mr. XU Hanxing as executive directors; Ms. ZHANG Lihua as non-executive director; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHEN Yujun as independent non-executive directors.*

\* *For identification purpose only*